Saturday 17 October 2026
Export XBIT’s income statement to Excel — free account
XBiotech Inc.
XBIT Healthcare Biotechnology
XBiotech Inc.’s revenue for fiscal 2022 (year ended December 2022) was $4.0 million. In the quarter to June 2026, EPS fell 266.7% and free cash flow grew 25.3%, each against the same quarter a year earlier.
2.12
0.04
−1.85%
Follow XBIT
XBiotech Inc. (XBIT) P/E ratio
XBiotech Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1.5× (January 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2022 | 0.0× | — |
| Sep 2022 | 0.0× | — |
| Jun 2022 | 0.0× | — |
| Mar 2022 | 0.0× | — |
| 8 more quarters | Free account |
Against its own ten years
Low 0.0×
High 1.5×
Ten-year median
0.0×
Current reading's percentile
91
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CSBR Champions Oncology, Inc. compare | n/m |
| HYFT MindWalk Holdings Corp. compare | n/m |
| VRCA Verrica Pharmaceuticals Inc. compare | n/m |
| XBIT XBiotech Inc. | n/m |
| NMAD Nomad Power Solutions, Inc. compare | n/m |
| CING Cingulate Inc. compare | n/m |
| OSTX OS Therapies Incorporated compare | n/m |
| FBIO Fortress Biotech, Inc. compare | 0.6× |
| SPRO Spero Therapeutics, Inc. compare | 7.9× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)